Meanwhile, it was suggested in the North American Neuroendocrine Tumor Society (NANETS) guidelines (23) that observation is an optimal choice for NF-PNETs ≤1 cm, while the management of NF-PNETs 1–2 cm should be considered on an individual basis according to some factors, including patient age, comorbidities, endoscopic ultrasonography–fine-needle aspiration or endoscopic ultrasonography–biopsy findings (grade, Ki-67), tumor growth status, anatomical location, extent of procedure required for complete resection, patient preferences, and access to long-term follow-up. The gene discussed is MKI67; the disease is neoplasm.